Mithra Announces Sale of Shares in Mayne Pharma

  • Sells 4,221,815 shares to reduce stake in Mayne Pharma to 4.96%
  • Shares acquired as part of agreement on US commercialization of Estelle®
  • Natural point to monetize investment, following authorization and launch in US
  • Remains major shareholder in Mayne Pharma and strong collaboration continues


Liege, Belgium, 16June 2023 – 8:50 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the sale of 4,221,815 shares in Mayne Pharma Group Limited (ASX: MYX) at a price of A$3.86 per share, in line with Mayne Pharma’s last close (ie 0% discount). The settlement is expected to take place at T+2 business days.

Mithra continues to hold 4,221,816 shares in Mayne Pharma, a leading Women’s Health player in oral contraceptives in the US, and its stake now corresponds to 4.96% of the outstanding shares in Mayne Pharma listed on ASX, from the previous 9.93%. The Company has no intention to divest its current participation in Mayne Pharma.

Mithra acquired the shares in Mayne Pharma as part of a License and Supply Agreement for an exclusive license to commercialize Estelle®, Mithra’s novel combined oral contraceptive, in the US, which was concluded in 2019. Under the terms of the agreement, Mithra had a seat on the Mayne Pharma Board of Directors and was involved in the steering committee for the US launch of Estelle®, under the trademark Nextstellis®.

David Horn Solomon, Chief Executive Officer of Mithra, commented: “As these shares were received as part of payment for US marketing rights to Estelle, it is time that we monetize them to provide cash for Mithra’s operations. We have made good progress in partnership with Mayne Pharma, including achieving US marketing authorization and the commercial launch. With the recent start of a direct-to-consumer campaign of television advertising, we are optimistic that our US marketing partner will increase Nextstellis® sales. We remain a major shareholder in Mayne Pharma and look forward to continuing our strong collaboration.”

There was a lockup period on the shares until market authorization for Estelle® was achieved in May 2021. A Mayne Pharma share buyback program, announced in May 2023, had raised the possibility of Mithra’s shareholding breaching a 9.9% threshold which it had agreed not to go above in the 2019 Master Share Purchase Agreement. Mithra does not currently intend to sell its remaining stake in Mayne Pharma.


Please read this carefully as it applies to all persons who visit this website. The following pages contain information relating to an offering and/or admission to trading on a regulated market in relation to securities of Mithra Pharmaceuticals SA ("Mithra Pharmaceuticals"). This information may not be accessed by residents of certain countries based on applicable securities law regulations. Accordingly, if you wish to access this part of the website you must first inform yourself about and then observe the statutory and regulatory requirements applicable to you and to your jurisdiction. In order to establish whether or not you may view the information and documents please read the disclaimer below in full.


This website and the information contained herein or to which it gives access are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the "United States"), Australia, Japan or South Africa, and do not constitute, or form part of, an offer or invitation to sell or issue, or a solicitation of an offer or invitation to purchase or subscribe for, nor shall there be any sale or purchase of, any securities of Mithra Pharmaceuticals in the United States, Australia, Japan or South Africa or in any other jurisdiction in which such offer, invitation, solicitation, sale, issue, purchase or subscription would be unlawful prior to registration, unless an exemption from registration or qualification under the securities laws of any such jurisdiction is applicable. The securities of Mithra Pharmaceuticals referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act. There will be no public offering of Mithra Pharmaceuticals' securities in the United States.

All persons residing outside of the United States, Australia, Canada, Japan and South Africa who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. Mithra Pharmaceuticals assumes no responsibility if there is a violation of applicable law and regulations by any person.

No action has been taken by Mithra Pharmaceuticals that would permit an offer of Mithra's securities or the possession or distribution of the materials to which this website gives access or any other offering or publicity material relating to Mithra's securities in any jurisdiction where action for that purpose is required.

Mithra Pharmaceuticals has not authorised any public offering in any Member State of the European Economic Area. With respect to any Member State of the European Economic Area that has implemented Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended from time to time (together with any applicable implementing measures in such Member State, the "Prospectus Regulation"), this website and the information contained herein, or to which it gives access, is only addressed to, and is only directed at, qualified investors in that Member State within the meaning of the Prospectus Regulation.

In addition, in the United Kingdom, this website and the information contained herein, or to which it gives access, is addressed to, and directed only at: (a) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), and (b) high net worth entities, and other persons to whom they may otherwise lawfully be communicated, falling within article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). In the United Kingdom, any investment or investment activity to which this website and the information contained herein, or to which it gives access, relates, is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this website and the information contained herein, or to which it gives access.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Access to electronic versions of these materials is being made available on this webpage by Mithra Pharmaceuticals in good faith and for information purposes only.

By checking the acceptance box below, you confirm and certify that: You are not a resident of or physically present in the United States, Australia, Canada, Japan or South Africa or any other restricted jurisdiction, and that you are either: (a) a resident of, and domiciled in, a Member State of the European Economic Area and a qualified investor within the meaning of the Prospectus Regulation, (b) a resident of, and domiciled in, the United Kingdom, a qualified investor within the meaning of the Prospectus Regulation and a Relevant Person, or (c) otherwise authorised to access this information pursuant to applicable laws or regulations.